Compare ADPT & LFST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADPT | LFST |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.8B |
| IPO Year | 2019 | 2021 |
| Metric | ADPT | LFST |
|---|---|---|
| Price | $28.14 | $13.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $30.21 | $14.45 |
| AVG Volume (30 Days) | 2.0M | ★ 2.8M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $276,976,000.00 | ★ $1,424,285,000.00 |
| Revenue This Year | $5.03 | $19.96 |
| Revenue Next Year | $22.97 | $14.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 54.77 | 13.85 |
| 52 Week Low | $12.00 | $4.78 |
| 52 Week High | $30.74 | $14.15 |
| Indicator | ADPT | LFST |
|---|---|---|
| Relative Strength Index (RSI) | 59.54 | 69.94 |
| Support Level | $23.73 | $11.73 |
| Resistance Level | $30.35 | $14.15 |
| Average True Range (ATR) | 1.47 | 0.41 |
| MACD | 0.32 | 0.15 |
| Stochastic Oscillator | 83.27 | 96.94 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.